Moleculin Biotech accelerates Phase 3 AML trial recruitment; targets 45 subjects for Q4 2025 unblinding

Moleculin Biotech, Inc.

13 subjects recruited (10 dosed); target of 20 by end of September 2025.
Expanding to 8 new active sites in September (Spain, Georgia, Poland, Romania, Italy, Lithuania, US) for total 20.
On track to recruit 45th subject in Q4 2025 for first unblinding of efficacy and safety data.
Expects to conclude Part A (75–90 subjects) in first half 2026, then commence Part B (~220 subjects).
CEO cites operational efficiency and investigator enthusiasm; over 30 active sites expected by year-end.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.